Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer

Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer

US Patent 10959993 · Granted Mar 30, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor fo2025
Treatment of cancer using combination therapies comprising GDC-6036 and GDC-00772025
Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding ant2024
Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor fo2024
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2023
Method of preparing carbon-based sulfur-loading iron-containing adsorbent for me2022
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2022
Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhib2021
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2021
Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibi2021
Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods2018
Methods and compositions for modulating estrogen receptor mutants2018